Dabrafenib + trametinib in patients w/rare BRAF V600E mutated solid tumor (CDRB436IIC01)
Clinical Trial Grant
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 25, 2025
End Date
October 7, 2029
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 25, 2025
End Date
October 7, 2029